Mr. Adam has over 40 years of board level and operational experience in big pharma. He has assumed executive roles in the mergers of Glaxo with Wellcome, and in the acquisition of biotechnology companies such as Affymax. He has sat on the executive committee of Glaxo Wellcome, the board of Glaxo Group Research, and at various times served as President and CEO of Glaxo’s operations in Japan and France. Amongst other senior posts at Glaxo, he has held the positions of Director of Commercial Strategy, and Director of International Marketing. Mr. Adam is an alumnus of Stanford Business School and a Chevalier de la Légion d’Honneur commended for services to the healthcare industry.
Dr Choo is the founder, CEO and CSO of Progenitor Therapeutics. He is also the founder of Plasticell Ltd, a leading stem cell technology and cell therapy company. Prior to his interest in stem cells he was a founder and Chief Scientist of Gendaq (1999-2001; acquired by Sangamo Biosciences), a biotech company that developed the zinc finger technology now used for gene editing. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge where he worked with Nobel laureate Professor Sir Aaron Klug. He serves on the UK Stem Cell Steering Committee, which oversees national stem cell research and the UK Stem Cell Bank.
Mr Foy is a Partner at SR One, the venture capital arm of GlaxoSmithKline. Previously he was a Vice President for Greenhill and Co, a mergers and acquisitions investment bank, where he worked for eight years up until 2010 in the New York and London offices. More recently he worked as a consultant for Longbow Capital Partners. Mr Foy holds a BSc and an MA in molecular biology from Oxford University, a Certificate in Corporate Finance from The London Business School and is FSA and SEC qualified.
Dr Harland is a Partner at SR One, the venture capital arm of GlaxoSmithKline. She has more than 20 years experience in the pharmaceutical industry during which she has gained extensive operational, drug development and licensing experience through numerous roles held in clinical development, medical affairs and business development. Dr Harland is a member of the board of directors of a number of SR One portfolio companies as well as Cancer Research Technology, the commercialisation and development arm of Cancer Research UK. Dr Harland holds a PhD in Pharmacology from the University of London and an MBA from Henley Management College.